Towards Healthcare
Oncology Biomarker Market to Lead USD 113.54 Bn by 2034

Oncology Biomarker Market Advancements in AI and Testing

The oncology biomarker market is valued at USD 38.62 billion in 2025 and is projected to reach USD 113.54 billion by 2034, growing at a CAGR of 12.73%. The report covers market segments by biomarker type, including genomic (35% share in 2024) and proteomic biomarkers, application types such as diagnostic testing (50% share in 2024) and prognostic testing, and cancer types including breast (25% share) and lung cancer, with regional insights across North America, Europe, Asia Pacific, Latin America, and MEA.

Content

  • Last Updated: 16 October 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Rohan Patil is a seasoned market research professional with over 5 years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.

He began his journey with Precedence Research, where he played a pivotal role in developing high-impact healthcare market reports. Today, Rohan leads research initiatives at Towards Healthcare, while also contributing to Statifacts, where he supports cross-industry analysis and data-driven storytelling.

Rohan’s core strengths lie in trend analysis and emerging technologies, regulatory monitoring and thought leadership through high-quality report writing. He excels at identifying future-ready opportunities and translating complex data into strategic recommendations. His work spans pharmaceuticals, biotechnology, medical devices, and digital health, assessing everything from market potential and competitive positioning to customer needs and regulatory shifts.

A trusted advisor and a relentless innovator, Rohan continues to push the boundaries of traditional market research, merging scientific rigor with commercial insight to stay ahead in a fast-evolving healthcare landscape.

Talk to us
FAQ's

The oncology biomarker market stands at USD 38.62 billion in 2025 and is expected to reach USD 113.54 billion by 2034, growing at a CAGR of 12.73% from 2024 to 2034.

North America is currently leading the oncology biomarker market share by 35% due to the presence of a robust healthcare infrastructure.

Some key players include F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., bioMérieux SA, and Merck & Co., Inc. 

The oncology biomarkers play a crucial role in early cancer detection, monitoring disease progression, and assessing therapeutic responses, as well as in the development of personalized medicine. 

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.
Any Questions